Eocene Announces its First European Sales and Distribution Agreement to Accelerate the Commercialization of Colospan's CG-100 Device
Eocene's subsidiary Colospan signed its first European distribution agreement for the CG-100 device, granting Hospital Line SA exclusive rights to market and sell in Greece and Cyprus. The agreement includes exclusivity and commercial targets, with a launch planned at the 17th Hellenic-Cypriot Surgical Conference, running in parallel with CG-100's ongoing U.S. pivotal study.
Key figures
- Drug Name
- CG-100
- Us status
- investigational use only; not approved for commercial use in the United States
- Exclusivity territories
- ["Greece","Cyprus"]
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.